ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
0.5884
-0.0186 (-3.06%)
Apr 25, 2025, 4:00 PM EDT - Market closed
ProMIS Neurosciences Employees
As of December 31, 2024, ProMIS Neurosciences had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
$347,359
Market Cap
19.23M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8 | 1 | 14.29% |
Dec 31, 2023 | 7 | 0 | - |
Dec 31, 2022 | 7 | 1 | 16.67% |
Dec 31, 2021 | 6 | 5 | 500.00% |
Dec 31, 2020 | 1 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
PMN News
- 26 days ago - ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 4 weeks ago - ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference - GlobeNewsWire
- 6 weeks ago - ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting - GlobeNewsWire
- 6 weeks ago - ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Issues Letter to Shareholders - GlobeNewsWire
- 5 months ago - ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewsWire